Antithrombotic treatment and intracerebral haemorrhage: between Scylla and Charybdis

Jeannette Hofmeijer, L.J. Kappelle, C.J.M. Klijn

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)


In patients who have intracerebral haemorrhage while on antithrombotic treatment, there is no evidence from randomised clinical trials to support decisions with regard to antithrombotic medication. In the acute phase, we advise stopping all antithrombotic treatment with rapid reversal of antithrombotic effects of oral anticoagulants. After the acute phase, we discourage restarting oral anticoagulants in patients with a lobar haematoma caused by cerebral amyloid angiopathy because of the high risk of recurrent bleeding. In these patients, even treatment with platelet inhibitors needs careful weighing of the risks of bleeding and ischaemic stroke. In patients with non-lobar intracerebral haemorrhage, we suggest considering restarting optimal antithrombotic treatment. This includes treatment with oral anticoagulants for patients with atrial fibrillation and/or mechanical valve prosthesis. After intracerebral haemorrhage during oral anticoagulant therapy in patients with atrial fibrillation, direct anticoagulants may be better than vitamin K antagonists, but we await confirmation of this from ongoing trials.
Original languageEnglish
Pages (from-to)250-256
Number of pages7
JournalPractical neurology
Issue number4
Publication statusPublished - 8 Jan 2015


  • METIS-313120
  • IR-98167


Dive into the research topics of 'Antithrombotic treatment and intracerebral haemorrhage: between Scylla and Charybdis'. Together they form a unique fingerprint.

Cite this